Elusys Therapeutics, Inc Overview
Company Headquarters: New Jersey, US
Founded: 1998
Workforce: ~25
Company Working: Elusys Therapeutics, Inc. is a commercial-stage biopharmaceutical company that develops antibody-based products to treat infectious diseases. It has partnerships with renowned biodefense associations, including the Centers for Disease Control and Prevention (US), the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (US), and the National Institute of Allergy and Infectious Diseases (US). It supplies its anthrax antitoxin products from the Strategic National Stockpile (US).
Moreover, it is a wholly owned subsidiary of NightHawk Biosciences (US) and is expanding NightHawk's biodefense space while also complementing NightHawk’s RapidVax platform, which is designed to specifically target emerging biological threats
Strategy
Elusys Therapeutics, Inc. is focusing on developing proprietary platform technologies designed to target emerging biological threats. This platform will enable the deployment of biodefense solutions that will assist in the development of fast, durable protection and effective treatment. It is also building relationships with government agencies to fulfill government demands during emerging and emergency disease conditions. Moreover, the company is using funds it has received from government agencies for R&D purposes to develop innovative infectious disease products.
